Ascentage Pharma Group International's quarterly market cap
increased
from Dec. 2024 ($847.96 Mil) to Jun. 2025 ($2,032.92 Mil) and
increased
from Jun. 2025 ($2,032.92 Mil) to Dec. 2025 ($3,165.77 Mil).
Ascentage Pharma Group International's annual market cap
declined
from Dec. 2023 ($931.53 Mil) to Dec. 2024 ($847.96 Mil) but then
increased
from Dec. 2024 ($847.96 Mil) to Dec. 2025 ($3,165.77 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Ascentage Pharma Group International's Enterprise Value for Today is $1,443.20 Mil.
Ascentage Pharma Group International (OTCPK:ASPHF) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Ascentage Pharma Group International Market Cap Related Terms
Ascentage Pharma Group International Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ascentage Pharma Group International Market Cap Chart
For the Biotechnology subindustry, Ascentage Pharma Group International's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ascentage Pharma Group International Market Cap vs Biotechnology Industry
Ascentage Pharma Group International Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ascentage Pharma Group International (ASPHF) has a Market Cap of $1,513.20 Mil as of Jun. 25, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Ascentage Pharma Group International and its competitors. According to the industry distribution chart, Ascentage Pharma Group International ranks #220 out of 1431 companies in the Biotechnology industry, placing it in the top 15.4%.
Is Ascentage Pharma Group International's Market Cap too high?
Ascentage Pharma Group International's current Market Cap is $1,513.20 Mil. The Biotechnology industry median Market Cap is 117.63. Ascentage Pharma Group International's value of $1,513.20 Mil is 1186.5% above this industry median. Based on the distribution chart, Ascentage Pharma Group International ranks #220 out of 1431 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Ascentage Pharma Group International has a GF Score™ of 71/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ascentage Pharma Group International's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ascentage Pharma Group International ranks #220 out of 1431 companies for Market Cap. This places Ascentage Pharma Group International in the top 15% of its industry — outperforming the majority of peers. The industry median Market Cap is 117.63. Ascentage Pharma Group International's value of $1,513.20 Mil is 1186.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 117.63, based on 1,431 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ascentage Pharma Group International's current Market Cap of $1,513.20 Mil is 1186.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Ascentage Pharma Group International and its competitors. For the Biotechnology industry, the median Market Cap is 117.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ascentage Pharma Group International's current Market Cap is $1,513.20 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascentage Pharma Group International stock overvalued right now?
Based on GuruFocus' analysis, Ascentage Pharma Group International (ASPHF) is currently considered Possible Value Trap. The stock's GF Value™ is $6.61, compared to a current price of $4.53 — trading 31.5% below its estimated fair value. The current Market Cap is $1,513.20 Mil and 1186.5% above the Biotechnology industry median of 117.63. Ascentage Pharma Group International's overall GF Score™ is 71/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Ascentage Pharma Group International (ASPHF), the current Market Cap is $1,513.20 Mil as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ascentage Pharma Group International (ASPHF) Overvalued in 2026?
Based on GuruFocus' analysis, Ascentage Pharma Group International stock appears to be undervalued.
The current stock price of $4.53 is trading 31.5% below its estimated GF Value™ of $6.61.
GuruFocus considers Ascentage Pharma Group International to be Possible Value Trap.
Key valuation signals for ASPHF:
Market Cap: $1,513.20 Mil
GF Value™: $6.61 vs. price of $4.53 (31.5% below fair value)
Industry Position: 1186.5% above the Biotechnology median (#220 of 1431)
No single metric tells the full story. See the ASPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ascentage Pharma Group International Business Description
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies and currently has seven drug candidates in pipeline under research. The company's geographical segments include the United States and Mainland China.
71GF Score
Get the complete analysis for ASPHF
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASPHF has been successfully added to your 
